With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Numerous successes in global health have been achieved over recent years, in part due to committed U.S. government leadership efforts that have addressed several issues facing the world's poorest people. The promise of potential solutions that can save millions more lives every year and strengthen other development efforts has captured the interest of a new generation of stakeholders eager to make a difference in an interconnected world. Even in a time of great economic challenges, significant advances in global health can be achieved and sustained that will benefit U.S. national interests as well as those of its partners.
Join the Global Health Council, the Institute of Medicine and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria for a briefing to identify critical global health issues over the next two years and some of the key policy considerations that will confront the 111th Congress.
Thurs., April 2, 2009
Rayburn House Office Building, Room 2200
Refreshments will be served
• Ruth Levine, Committee on the US Commitment to Global Health, Institute of Medicine & Vice President for Programs and Operations, and Senior Fellow, Center for Global Development
• Natasha Bilimoria, Executive Director, Friends of the Global Fight
• Maurice Middleberg, Executive Vice President, Global Health Council
Moderator: Smita Baruah, Director of Government Relations, Global Health Council
If you plan to attend please click here to fill out our online form.
The Global Health Council Policy Series is funded in part through the Bill & Melinda Gates Foundation and with unrestricted educational support from the Abbott Fund and Merck & Co., Inc.